Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy.

Authors

E. S. Antonarakis

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

E. S. Antonarakis , A. S. Kibel , D. W. Lin , R. C. Tyler , M. Tabesh , C. G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer.

First Author: Isobel Porter

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).

First Author: Bertrand F. Tombal

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).

First Author: Bridget F. Koontz

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.

First Author: Deepak Kilari